China Healthcare Weekly (Apr.28)-TCM Formula Granule Outlook, Reduce CAR-T's Price, Gan & Lee Pharma

345 Views28 Apr 2024 15:38
TCM formula granule VBP brings challenge for company, but it also brings hope. There're breakthrough point of CAR-T's price decline. Gan & Lee has recovered from VBP, with further rebound ahead
What is covered in the Full Insight:
  • Performance Analysis of TCM Formula Granule Enterprises
  • Challenges and Progress in CAR-T Therapy
  • Overview of Gan & Lee Pharmaceuticals’ Core Insulin Business
  • Market Review
  • Risk Disclosure
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x